Autobio(SH:603658) Sou Hu Cai Jing·2025-08-12 08:21Core Insights - Antu Biology (603658) reported a closing price of 42.28 yuan as of August 12, 2025, with a slight decline of 0.14% [1] - The company experienced a total revenue of 996 million yuan in Q1 2025, representing a year-on-year decrease of 8.56% [1] - Net profit attributable to shareholders was 270 million yuan, down 16.76% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 996 million yuan, down 8.56% year-on-year [1] - Net profit: 270 million yuan, down 16.76% year-on-year [1] - Non-recurring net profit: 257 million yuan, down 18.19% year-on-year [1] - Current ratio: 2.625 [1] - Quick ratio: 2.149 [1] - Debt-to-asset ratio: 25.05% [1] Market Activity - The stock had a turnover rate of 0.86% with a trading volume of 49,100 lots and a transaction amount of 207 million yuan [1] - Net inflow of main funds was 12.63 million yuan, accounting for 6.09% of the transaction amount [1] - Large orders saw a net inflow of 15.30 million yuan, while small orders had a net outflow of 11.99 million yuan [1] Company Background - Antu Biology was established in 1999 and is located in Zhengzhou, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 5.71424768 billion yuan and a paid-in capital of 378 million yuan [1][2] - The legal representative of the company is Yang Zengli [1] Investment and Intellectual Property - Antu Biology has invested in 19 enterprises and participated in 1,182 bidding projects [2] - The company holds 83 trademark registrations and 598 patent registrations [2] - Additionally, it possesses 1,558 administrative licenses [2]